Spain Preclinical Cro Market Size & Outlook, 2023-2030
Spain preclinical cro market, 2018-2030 (US$M)
Related Markets
Spain preclinical cro market highlights
- The Spain preclinical cro market generated a revenue of USD 55.6 million in 2023 and is expected to reach USD 85.6 million by 2030.
- The Spain market is expected to grow at a CAGR of 6.3% from 2024 to 2030.
- In terms of segment, toxicology testing was the largest revenue generating service in 2023.
- Bioanalysis and DMPK studies is the most lucrative service segment registering the fastest growth during the forecast period.
Preclinical cro market data book summary
| Market revenue in 2023 | USD 55.6 million |
| Market revenue in 2030 | USD 85.6 million |
| Growth rate | 6.3% (CAGR from 2023 to 2030) |
| Largest segment | Toxicology testing |
| Fastest growing segment | Bioanalysis and DMPK studies |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology |
| Key market players worldwide | Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA |
Other key industry trends
- In terms of revenue, Spain accounted for 1.0% of the global preclinical cro market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK preclinical cro market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 748.8 million by 2030.
Toxicology testing was the largest segment with a revenue share of 26.08% in 2023. Horizon Databook has segmented the Spain preclinical cro market based on bioanalysis and dmpk studies, toxicology testing, compound management, chemistry, safety pharmacology covering the revenue growth of each sub-segment from 2018 to 2030.
Spain offers great potential in the preclinical CRO market. It is considered to be a lucrative market for conducting preclinical trials due to the presence of highly developed laboratories & skilled workforce, proven research quality along with high presence of well-established pharmaceutical & biotechnology industries. According to Invest in Spain, private investment in the biotechnology sector is anticipated to exceed USD 197.16 million in 2021.
Similarly, the pharmaceutical industry in Spain leads in terms of R&D spending. This sector accounts for 19.6% of private R&D spending in the country, with pharmaceutical companies allocating over 50% of their resources to clinical trials.
The country offers robust support through different government initiatives, regulatory advice, research activities, and biotechnology companies, contributing to market growth.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Preclinical CRO Market Scope
Preclinical CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Spain preclinical cro market size, by service, 2018-2030 (US$M)
Spain Preclinical CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
